Sleep-endocrine profile of the antidepressant mianserin.
The effects of mianserin, a tetracyclic antidepressant, on sleep stages and on the nocturnal secretion of cortisol, ACTH, growth hormone, prolactin and tryptophan were studied on 11 normal male volunteers in a double-blind, placebo-controlled study. Mianserin increased Stage 3 time (p less than 0.001) and Stage 4 time (p less than 0.01). It reduced the number of REM periods (p less than 0.001), the REM latency after sleep onset (p less than 0.01) and both the total and percentage REM time (p less than 0.05). A reduction in both the total sleep time (p less than 0.05) and the percentage of  total time in bed (p less than 0.05) were the only significantly carry-over effects from the drug treatment period. No significant difference in any biochemical measurement was found between placebo and drug treatment.
D000328:Adult; D003984:Dibenzazepines / Q000494:pharmacology*; D004311:Double-Blind Method; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D008297:Male; D008803:Mianserin / Q000494:pharmacology*; D010907:Pituitary Hormones / Q000378:metabolism*; D010919:Placebos; D012894:Sleep Stages / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects; D014364:Tryptophan / Q000378:metabolism*
D003984:Dibenzazepines; D010907:Pituitary Hormones; D010919:Placebos; D008803:Mianserin; D014364:Tryptophan; D006854:Hydrocortisone